Previous close | 20.15 |
Open | 20.19 |
Bid | 18.10 |
Ask | 19.45 |
Strike | 105.00 |
Expiry date | 2024-01-19 |
Day's range | 20.15 - 20.45 |
Contract range | N/A |
Volume | |
Open interest | 448 |
The FDA is asking COVID-19 vaccine makers to test and produce boosters that target both the original and new BA.4/BA.5 strains of the virus by fall.
Shares of Moderna (NASDAQ: MRNA) have been plummeting in recent months. As concerns shift from COVID-19 and onto inflation, investors have become less bullish on Moderna's stock. Omicron was a significant variant when it emerged in November, and that prompted Moderna to create a booster shot which targeted that variant.
Prior to the pandemic, Moderna (NASDAQ: MRNA) was like many other small biotechs. In fact, for the full year of 2019, Moderna had only $60 million in revenue, entirely from collaborations and grants, and it posted a net loss of $514 million. As we know, Moderna's ability to rapidly produce a vaccine for the COVID-19 virus changed the financial prospects for the company and put it in a completely different position today.